GlycoNex to advance development of novel pro-antibody cancer drugs that enhance tumor suppression while minimizing off-site binding to healthy tissues to improve safety and tolerability NEW TAIPEI CITY, Taiwan, May 28, 2024 /PRNewswire/ — GlycoNex (4168, hereinafter referred to as GNX),…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.